Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to prospectively assess the histopathological response to neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab in peritoneal tumor deposits of 30 patients with pcCRC by determining the % of viable tumor cells (vtc) in the resected specimen after neoadjuvant chemotherapy using standard pathology. In case of multiple specimens, the median % of viable cells will be calculated and used for analysis. The timepoint of the assessment of the primary objective will be during re-exploratory surgery/surgical cytoreduction between days 78 and 106 of the treatment phase of the study. We hypothesize that there will be >30% responders after neoadjuvant FOLFOXIRI + bevacizumab treatment. Responders will be defined as patients with pCR (0% vtc) and major response (1-49% vtc) after FOLFOXIRI + bevacizumab chemotherapy. Non-responders will be defined as patients with minor/no response (≥50% vtc) after FOLFOXIRI + bevacizumab chemotherapy.
Critère d'inclusion
- Patients with peritoneal carcinomatosis from colorectal cancer are treated with a combination chemotherapy (FOLFOXIRI+ Bevacizumab)